Urinary tract infection: FDA reporting patterns
167,825 FDA FAERS reports mention Urinary tract infection. 126,930 reports have a serious outcome flag.
Medicines named as suspect
- Adalimumab: 8,868 reports
- Etanercept: 6,323 reports
- Natalizumab: 6,126 reports
- Lenalidomide: 4,991 reports
- Ocrelizumab: 3,696 reports
- Interferon Beta-1a: 3,565 reports
- Methotrexate: 3,281 reports
- Tofacitinib: 3,261 reports
- Dalfampridine: 3,177 reports
- Rituximab: 3,173 reports
- Infliximab: 3,010 reports
- Levodopa: 2,442 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.